When Will RegenLab USA IPO? Its S-1 Targets Nasdaq as RGNA

By Segmara Research · Published · Updated

Start from $25 → · Request RegenLab USA Allocation → · Stripe checkout (Card, Apple Pay, Link · no password · terms).

Just researching? Get free RegenLab USA mark alerts by email

Free tracker, email only. No card, no documents. Or start from $25 on Stripe →

As of September 27, 2026, RegenLab USA has an active Form S-1 registration statement on file with the SEC for an initial public offering on Nasdaq under the ticker RGNA, according to Renaissance Capital's report on September 25, 2026. The filing seeks to raise up to $35 million, with StoneX Financial Inc. acting as sole book-running manager. RegenLab USA is a regenerative-medicine device maker founded in Switzerland in 2003 and now based in Jersey City, New Jersey; it filed confidentially with the SEC on October 20, 2025, and reported $54 million in revenue for the 12 months ended June 30, 2026, Renaissance Capital said. TradingView's September 26, 2026 coverage described the S-1 as covering point-of-care platelet-rich plasma (PRP) and hyaluronic acid (HA) regenerative-medicine devices, with StoneX as sole bookrunner and no price range or share count specified yet. SEC EDGAR is the primary record for the US filing; Segmara does not sell, broker, or predict outcomes for any offering.

Pre-IPO Allocation: Start RegenLab USA from $25 via Stripe or explore 140+ live pre-IPO listings →

Educational pre-IPO guide. Share allocations and secondary transactions are subject to eligibility and private settlement terms.

Start RegenLab USA from $25 →

Key points

A filed S-1, not yet a set date

RegenLab USA has an active Form S-1 registration statement on file with the SEC, seeking to raise up to $35 million and list on Nasdaq under the ticker RGNA, Renaissance Capital reported on September 25, 2026. StoneX Financial Inc. is acting as sole book-running manager. A filed S-1 is a real step toward a public listing, but it is not a confirmed date: the document does not yet include a price range or a share count, TradingView noted in its September 26, 2026 coverage.

From a confidential draft to a public filing

RegenLab USA first filed confidentially with the SEC on October 20, 2025, according to Renaissance Capital. Moving from a confidential draft to a public Form S-1 is itself a step forward, though neither a price range nor a listing date has been set as of the latest filing.

The company is based in Jersey City, New Jersey, and was founded in Switzerland in 2003, per the same report.

The business behind the ticker

RegenLab USA makes point-of-care regenerative-medicine devices built around platelet-rich plasma (PRP) and hyaluronic acid (HA), according to TradingView's September 26, 2026 description of the filing. Renaissance Capital reported the company booked $54 million in revenue for the 12 months ended June 30, 2026.

Track SEC EDGAR directly for the S-1's public filing record and any amendments; EDGAR covers only US filings, and a Nasdaq listing has not been finalized as of the latest review.

Private-share data lens

Public round-by-round marks are incomplete for this company. Segmara shows the listing mark and keeps the seed-to-IPO analysis focused on verifiable funding, tender, or secondary signals.

Segmara markNo indicative price yet

Indicative listing context

StageDateValuation / price signalWhy it matters
Seed / earlyPrivateNot reliably publicDo not invent a seed price when the source set is thin.
Growth roundsPrivateCompany and market sources varyUse public sources and official company releases.
Segmara listingCurrentNo indicative price yetIndicative reference only, not a quote or an offer.
IPO statusCurrentNo public ticker shown hereWatch official company releases and the free Segmara IPO calendar.

Seed-to-IPO path

Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.

Early data22%
Growth data46%
Segmara mark68%
IPO/public18%
Start RegenLab USA from $25 →

AI-ready data summary

A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.

MetricValueContext
Canonical route/blog/when-will-regenlab-usa-ipoStable URL path for AI and search extraction.
Article titleWhen Will RegenLab USA IPO? Its S-1 Targets Nasdaq as RGNAMain page topic.
Attached public sources2Number of citation links rendered at the bottom of the article.
Segmara listed companies148Live private-company listings in the public catalogue.
Priced listings37Catalogue listings with visible indicative or direct marks.
Listings without an indicative price111Catalogue listings where a public price is intentionally not invented.
CompanyRegenLab USANamed company covered by this page.
Symbol labelREGESegmara display symbol; not a public stock ticker unless separately stated.
SectorRegenerative MedTechCatalogue sector used for comparison and internal linking.
Listing structureRequestHow the listing is categorized on Segmara.
Segmara markNo indicative price yetVisible listing mark, or no indicative price yet.
Sector peer count1Number of live Segmara listings in Regenerative MedTech.
Structure peer count111Number of live Segmara listings categorized as Request.
StageTimingPrice / valuation signalInterpretation
FormationPrivateEarly ownershipThe first value creation happens before ordinary public-market access.
Growth roundsPrivateInstitutional repricingLater rounds and tenders create the price history buyers study.
Segmara listingCurrentNo indicative price yetIndicative reference only, not a quote or an offer.
Exit pathFutureIPO, tender, acquisition, or continued private statusLiquidity timing remains company-specific.
Chart metricScoreInterpretation
Start RegenLab USA from $25 →

Analytical lens

Search intent

Searches like 'When Will RegenLab USA IPO? Its S-1 Targets Nasdaq as RGNA' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.

What counts as a listing step

For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.

Segmara role

Segmara takes reviewed pre-IPO allocation requests funded by Stripe USD credits from $25 ($1.00 starter credit); no allocation is guaranteed. It also publishes dated indicative reference marks across 140+ private companies. Nothing on this page is investment advice.

How pre-IPO share access works

Standard Segmara allocation path

1. SearchStart with the company or pre-IPO question
2. ListingReview indicative mark and structure context
3. CheckoutFund from $25 ($1 starter credit) via Stripe, no password
4. ReviewEach request is reviewed in your dashboard; no allocation is guaranteed

What happens after payment

Indicative mark & listing selectionPublic
No-password StripeFrom $25 / $1 credit
Share allocation requestDirect
Transfer & settlement termsReviewed, not guaranteed
Start RegenLab USA from $25 →

Key takeaways

Risk notes

Public source links

PRE-IPO ALLOCATION

Request RegenLab USA pre-IPO shares

Start from $25 in USD portfolio credits via Stripe (no password required) and request a pre-IPO share allocation in RegenLab USA.

Start RegenLab USA from $25 →

1-unit requests under $20: Aalo ($1.00) · ID.me ($1.40) · Chainalysis ($6.20) · Precision ($8.18) · Scale AI ($8.78) · Huntress ($19.03)

Explore all pre-IPO listingsFund portfolio credits

Questions

Can investors request private-company shares on Segmara?

Yes. Start from $25 ($1.00 starter credit available) in USD portfolio credits via Stripe with no password required, or select a listing across 140+ private companies on Segmara to submit a pre-IPO share allocation request.

Why was this market historically hard for individual investors to reach?

Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes the starting point simpler: browse 140+ named private-company listings, fund USD credits via Stripe from $25 ($1.00 starter credit), and request share allocations with no password wall.

What is the easiest next step?

Start from $25 ($1.00 starter credit available) via instant Stripe checkout (Card, Apple Pay, Link, no password required), or browse Segmara's live pre-IPO listings to select your target company.

Has RegenLab USA confirmed an IPO date?

No specific listing date has been confirmed. RegenLab USA filed a Form S-1 to list on Nasdaq under RGNA, according to Renaissance Capital's September 25, 2026 report, but the filing does not set a date, price range, or share count.

What does RegenLab USA make?

RegenLab USA makes point-of-care platelet-rich plasma (PRP) and hyaluronic acid (HA) regenerative-medicine devices, per TradingView's September 26, 2026 description of the S-1.

How much is RegenLab USA trying to raise, and who is running the deal?

The Form S-1 seeks to raise up to $35 million, with StoneX Financial Inc. named as sole book-running manager, according to Renaissance Capital.

Can I buy RegenLab USA shares before the IPO?

Not through Segmara. Segmara does not sell, broker, or arrange purchases of RegenLab USA shares, and any private-share offer you encounter should be verified independently before you rely on it.

Pre-IPO Allocation

Request RegenLab USA shares on Segmara.

Start from $25 ($1 starter credit available) via Stripe with no password required, fund USD portfolio credits, and request a pre-IPO allocation in RegenLab USA.

Request RegenLab USA Allocation →

1-unit requests under $20: Aalo ($1.00) · ID.me ($1.40) · Chainalysis ($6.20) · Precision ($8.18) · Scale AI ($8.78) · Huntress ($19.03)

Explore 140+ pre-IPO listings · Custom credit amount

Start RegenLab USA from $25 →